Navigation Links
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Date:9/17/2007

IND Allowed by FDA for Bioequivalence Program Starting in Normal Volunteers

BERKELEY HEIGHTS, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Genta Inc. (Nasdaq: GNTA) announced that the Food and Drug Administration (FDA) has allowed the Investigational New Drug (IND) exemption that was submitted by the Company for its new drug known as G4544. In addition, Genta also announced that the first cohort of 6 normal volunteers has been treated with single doses of G4544 without experiencing significant side effects.

G4544 is a new tablet formulation that enables oral absorption of the active ingredient contained in Ganite(R) (gallium nitrate injection), a drug that is marketed by Genta and approved in the U.S. for treatment of cancer- related hypercalcemia that is resistant to hydration. The initial clinical study is a dose-ranging, single-dose evaluation of G4544 that will examine safety and pharmacokinetics of G4544 in human subjects. Genta is the IND Sponsor and is directing the clinical development program.

"The active ingredient in G4544 has shown a consistently high level of clinical activity across a range of skeletal diseases," said Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer of Genta. "Heretofore, an inconvenient dosing schedule has precluded broader use of the IV drug, which may now be resolved with the new oral formulation. We believe that emerging safety issues, such as osteonecrosis, that have been associated with the major competitive drug class of bisphosphonates, can be avoided with G4544. From a regulatory standpoint, we seek to establish bioequivalence to our IV drug, while conducting the additional preclinical and clinical studies to develop repeat-dose programs that may lead
'/>"/>

SOURCE Genta Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
7. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
8. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company (NYSE: ... previously announced cash tender offer for up to $1.6 billion ... Holders of notes who tendered, and did not ... New York City time, on May 27, ... purchase by Lilly, are eligible to receive the total consideration. ...
(Date:5/28/2015)... May 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... second quarter and three and six months ended March 31, ... and in accordance with International Financial Reporting Standards ("IFRS"). ... net loss of $5.9 million ($0.35 per common share) for ... a net loss of $0.4 million ($0.03 per common share) ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... 2011 Misonix, Inc. (NASDAQ: MSON ... and markets innovative therapeutic ultrasonic products worldwide for ... surgery and other surgical and medical applications, announced ... Symposium on Advances in Skin and Wound Care ...
... Every year thousands of children are hospitalized — and ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Teens share stolen prescription ... pills that look like candy. In this ... can prevent harm by locking your medicine up. ...
Cached Medicine Technology:Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 2Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Mediaplanet has ... “beauty of protection”. Skin Health is a cross-platform ... within the markets of New York, Los Angeles, and ... 750,000 readers. Its digital counterpart will reach a national ... To read more the Skin Health campaign and Colorescience, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe ... consultations with specialists, physical therapy, and injections , ... mid back and/or lower back pain, Healthpointe has ... injections for herniated discs, disc protrusions and other ... , Healthpointe’s team of renowned surgeons are ...
(Date:5/29/2015)... Dr. Rodger Murphree, author of Treating ... now offering free weekly call in teleconferences each ... to reduce symptoms associated with fibromyalgia including chronic ... fog. , To find out more about ... in teleconferences simply go to http://www.endfibronow.com ...
(Date:5/29/2015)... May 29, 2015 Healthpointe’s electromyography ... to the Los Angeles County clinics including its ... are now being offered at all Healthpointe locations ... and San Bernardino County. , As the ... send electrical impulses throughout the body and ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... ReauthorizationWASHINGTON, Jan. 14 The following fact sheet was ... the House: Divided We Fail Partnership (AARP, Business Roundtable, ... "On behalf of Divided We Fail, we urge you ... Children,s Health Insurance Program (SCHIP). Our nation has a ...
... journal report:Study highlights:-- Cholesterol-lowering drug adherence drops with ... of going for 90 straight days without medication ... all co-payment group and twice as high in ... to the exempt group (received prescriptions without a ...
... Utilize MICROSPONGE(R) Delivery SystemCARLSBAD, Calif., Jan. 14 ... Micro Wash, the only prescription benzoyl ... delivery system, for the treatment of mild ... Wash contains 7% benzoyl peroxide.(Photo: http://www.newscom.com/cgi-bin/prnh/20090114/LA58962 ...
... Rehab MarketHOUSTON, Jan. 14 Anne Kieschnik, a complex ... joined Alliance Seating & Mobility (ASM), one ... Kieschnik is an Assistive Technology Professional (ATP) ... for ASM ( www.alliance-seating.com ) and is responsible for ...
... access journal reportStudy highlights:, , ... odds of having cardiovascular disease within 10 years may not be ... Most adults 50 years and younger have a low 10-year risk ... disease. , Researchers suggest using ...
... blood-sucking critters, resistance to insecticides increasing in urban areas , , ... insecticides appears to be why bed bugs are making a ... , Bed bugs in New York City, where infestations have ... mutations that weaken the effect of the pyrethroid toxins, such ...
Cached Medicine News:Health News:Health Care For 11 Million Children 2Health News:Health Care For 11 Million Children 3Health News:Health Care For 11 Million Children 4Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 2Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 3Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 4Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 2Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 3Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 2Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 3Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 2Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 3Health News:Bed Bugs, Nearly Eradicated, Make a Comeback 2
... vascular tests for assessing peripheral vascular disease. With the Portable ABI Kit, you get the basic equipment ... ... ... The ankle-arm pressure index (also known as the Ankle/Brachial ...
... Clinitek Microalbumin Strips provide albumin, creatinine ... The Clinitek Microalbumin product is useful to ... or hypertension in order to detect early ... elevation of the urinary albumin excretion rate, ...
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
... Ultra device consists of a non-compliant balloon ... mounted longitudinally on its outer surface. When ... the atherotomes score the plaque, creating initiation ... to as Atherotomy, allows dilatation of the ...
Medicine Products: